As we age, there are many possible changes that can increase our risk of falling. These changes may affect how we are able to compensate for balance when our muscles are tired. The goal of this research study is to understand how fatiguing (tiring) specific muscles can impact our ability to respond to different balance challenges in daily life.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.

If you are a healthy adult, you may be able to take part in a research study where you'll give us samples of your blood and saliva. In this study, we want to find out if we get similar results when we measure the same biomarkers from your blood and your saliva.

Do you have cancer that has come back after your first round of treatment and your tumor has tested positive for folate receptor-alpha (FRα)? A new study drug called mirvetuximab soravtansine (MIRV) is being studied as a possible treatment for your type of cancer

Researchers want to learn more about a new medication that could be used to treat adults with Eosinophilic Esophagitis (also called "EoE").

Have you been diagnosed with a precancerous breast condition that places you at "high risk" for breast cancer? If so, you may be able to take part in a research study looking at giving a new study drug ruxolitinib as a potential drug to prevent breast cancer.

Researchers want to learn more a new medication that could be used to treat adults with Eosinophilic Esophagitis (also called "EoE").

To determine the change from baseline to post-treatment values in HR-positive, HER2-negative invasive lobular carcinoma tissue derived from postmenopausal women awaiting definitive surgery or further treatment.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.